Metal ions, Alzheimer's disease and chelation therapy

D. Skovronsky, 2006, Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications, Annu. Rev. Pathol. Mech. Dis, 1, 151, 10.1146/annurev.pathol.1.110304.100113

R. Mayeux, 2003, Epidemiology of neurodegeneration, Annu. Rev. Neurosci, 26, 81, 10.1146/annurev.neuro.26.043002.094919

C. P. Ferri, R. Sousa, E. Albanese, W. S. Ribeiro and M. Honyashiki, <i>World Alzheimer Report 2009 - Executive Summary</i> (Eds. M. Prince and J. Jadeson), Alzheimer's Disease International, London 2009, pp. 1-22; <a target="_blank" href='http://www.alz.co.uk/adi/publications.html'>http://www.alz.co.uk/adi/publications.html</a>

F. LaFerla, 2005, Alzheimer's disease: Aβ, tau and synaptic dysfunction, Trends Mol. Med, 11, 170, 10.1016/j.molmed.2005.02.009

M. Tolnay, 1999, Tau protein pathology in Alzheimer's disease and related disorders, Neuropathol. Appl. Neurobiol, 25, 171, 10.1046/j.1365-2990.1999.00182.x

C. Ballatore, 2007, Tau-mediated neurodegeneration in Alzheimer's disease and related disorders, Nature Rev. Neurosci, 8, 663, 10.1038/nrn2194

C. Scott, 1993, Aggregation of tau protein by aluminum, Brain Res, 628, 77, 10.1016/0006-8993(93)90940-O

A. Yamamoto, 2003, Iron (III) induces aggregation of hyperphosphorylated tau, and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease, J. Neurochem, 86, 1137, 10.1046/j.1471-4159.2002.01061.x

R.-W. Shin, 2003, A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease, Brain Res, 961, 139, 10.1016/S0006-8993(02)03893-3

T. Lührs, 2005, 3D structure of Alzheimer's amyloid-β (1-42) fibrils, Proc. Natl Acad. Sci. USA, 102, 17342, 10.1073/pnas.0506723102

W. Esler, 2001, A portrait of Alzheimer secretases - new features and familiar faces, Science, 293, 1449, 10.1126/science.1064638

M. Mattson, 2004, Pathways towards and away from Alzheimer's disease, Nature, 430, 631, 10.1038/nature02621

M. Shoji, 1992, Production of the Alzheimer amyloid beta protein by normal proteolytic processing, Science, 258, 126, 10.1126/science.1439760

C. Masters, 1985, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc. Natl Acad. Sci. USA, 82, 4245, 10.1073/pnas.82.12.4245

B. Clippingdale, 2001, The amyloid-β peptide and its role in Alzheimer's disease, J. Peptide Sci, 7, 227, 10.1002/psc.324.abs

C. Vigo-Pelfrey, 1993, Amyloid peptide from human cerebrospinal fluid, J. Neurochem, 61, 1965, 10.1111/j.1471-4159.1993.tb09841.x

P. Seubert, 1992, Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids, Nature, 359, 325, 10.1038/359325a0

J. Jarret, 1993, The C-terminus of the β protein is critical in amyloidogenesis, Ann. NY Acad. Sci. USA, 695, 144, 10.1111/j.1749-6632.1993.tb23043.x

A. Lorenzo, 1994, Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red, Proc. Natl. Acad. Sci. USA, 91, 12243, 10.1073/pnas.91.25.12243

J. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994

H. Kozlowski, 2009, Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation), Coord. Chem. Rev, 253, 2665, 10.1016/j.ccr.2009.05.011

Y. Hung, 2010, Copper in the brain and Alzheimer's disease, J. Biol. Inorg. Chem, 15, 61, 10.1007/s00775-009-0600-y

P. Crouch, 2006, Therapeutic Treatments for Alzheimer's disease based on metal bioavailability, Drug News Perspect, 19, 469, 10.1358/dnp.2006.19.8.1021492

M. Lovell, 1998, Copper, iron and zinc in Alzheimer's disease senile plaques, J. Neurol. Sci, 158, 47, 10.1016/S0022-510X(98)00092-6

C. Atwood, 1998, Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis, J. Biol. Chem, 273, 12817, 10.1074/jbc.273.21.12817

B. Raman, 2005, Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid β peptide, J. Biol. Chem, 280, 16157, 10.1074/jbc.M500309200

P. Faller, 2009, Copper and zinc binding to amyloid-β: Coordination, dynamics, aggregation, reactivity and metal-ion transfer, ChemBioChem, 10, 2837, 10.1002/cbic.200900321

C. Hureau, 2009, A[beta]-mediated ROS production by Cu ions: Structural insights, mechanisms and relevance to Alzheimer's disease, Biochimie, 91, 1212, 10.1016/j.biochi.2009.03.013

M. Deibel, 1996, Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress, J. Neurol. Sci, 143, 137, 10.1016/S0022-510X(96)00203-1

M. Boll, 2008, Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases, Neurochem. Res, 33, 1717, 10.1007/s11064-008-9610-3

I. Maurer, 2000, A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients, Neurobiol. Aging, 21, 455, 10.1016/S0197-4580(00) 00112-3

Q. Ma, 2006, Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS, Peptides, 27, 841, 10.1016/j.peptides.2005.09.002

N. Watt, 2011, The role of zinc in Alzheimer's disease, Int. J. Alzheimer's Dis, 2011, 10.4061/2011/971021

A. Bush, 1994, Rapid induction of Alzheimer A beta amyloid formation by zinc, Science, 265, 1464, 10.1126/science.8073293

K. Lim, 2007, Investigations of the molecular mechanism of metal-induced Aβ (1-40) amyloidogenesis, Biochemistry, 46, 13523, 10.1021/bi701112z

C. Talmard, 2007, Amyloid-beta peptide forms monomeric complexes with Cu^II and Zn^II prior to aggregation, ChemBioChem, 8, 163, 10.1002/cbic.200600319

M. Cuajungco, 2003, Zinc takes the center stage: its paradoxical role in Alzheimer's disease, Brain Res. Rev, 41, 44, 10.1016/S0165-0173(02)00219-9

Z.-Y. Mo, 2009, Low micromolar zinc accelerates the fibrillization of human tau via bridging of Cys-291 and Cys-322, J. Biolog. Chem, 284, 34648, 10.1074/jbc.M109.058883

P. Mantyh, 1993, Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide, J. Neurochem, 61, 1171, 10.1111/j.1471-4159.1993.tb03639.x

C. Opazo, 2002, Metalloenzyme-like activity of Alzheimer's disease β-amyloid, J. Biol. Chem, 277, 40302, 10.1074/jbc.M206428200

D. Smith, 2007, The redox chemistry of the Alzheimer's disease amyloid beta peptide, Biochim. Biophysi. Acta - Biomembranes, 1768, 1976, 10.2217/14796708.2.4.397

P. Good, 1992, Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study, Ann. Neurol, 31, 286, 10.1002/ana.410310310

I. Klatzo, 1965, Experimental production of neurofibrillary degeneration: 1. Light microscopic observations, J. Neuropathol. Exp. Neurol, 24, 187, 10.1097/00005072-196504000-00002

R. Terry, 1965, Experimental production of neurofibrillary degeneration: 2. Electron microscopy, phosphatase histochemistry and electron prose analysis, J. Neuropathol. Exp. Neurol, 24, 200, 10.1097/00005072-196504000-00003

D. Drago, 2008, Potential pathogenic role of β-amyloid1-42-aluminum complex in Alzheimer's disease, Int. J. Biochem. Cell Biol, 40, 731, 10.1016/j.biocel.2007.10.014

A. Rauk, 2009, The chemistry of Alzheimer's disease, Chem. Soc. Rev, 38, 2698, 10.1039/b807980n

L. Scott, 2009, Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease, Chem. Rev, 109, 4885, 10.1021/cr9000176

J. Duce, 2010, Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics, Prog. Neurobiol, 92, 1, 10.1016/j.pneurobio.2010.04.003

I. Bush, 2008, Therapeutics for Alzheimer's disease based on the metal hypothesis, Neurotherapeutics, 5, 421, 10.1016/j.nurt.2008.05.001

A. Gaeta, 2005, The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy, Br. J. Pharmacol, 146, 1041, 10.1038/sj.bjp.0706416

P. Zatta, 2009, Alzheimer's disease, metal ions and metal homeostatic therapy, Trends Pharmacol. Sci, 30, 346, 10.1016/j.tips.2009.05.002

L. Perez, 2010, Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease, Dalton Trans, 39, 2177, 10.1039/b919237a

D. McLachlan, 1991, Intramuscular desferrioxamine in patients with Alzheimer's disease, Lancet, 337, 1304, 10.1016/0140-6736(91)92978-B

R. Cherny, 1999, Aqueous dissolution of Alzheimer's disease abeta amyloid deposits by biometal depletion, J. Biol. Chem, 274, 23223, 10.1074/jbc.274.33.23223

R. Cherny, 2000, Chelation and intercalation: Complementary properties in a compound for the treatment of Alzheimer's disease, J. Struct. Biol, 130, 209, 10.1006/jsbi.2000.4285

C. Boldron, 2005, Preparation of cyclo-phen-type ligands: Chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases, ChemBioChem, 6, 1976, 10.1002/cbic.200500220

A. Dedeoglu, 2004, Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis, Exp. Gerontol, 39, 1641, 10.1016/j.exger.2004.08.016

Z. Cui, 2005, Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases, Eur. J. Pharm. Biopharm, 59, 263, 10.1016/j.ejpb.2004.07.009

J.-Y. Lee, 2004, The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human [beta]-amyloid precursor protein transgenic mice, Neurobiol. Aging, 25, 1315, 10.1016/j.neurobiolaging.2004.01.005

V. Moret, 2006, 1,1 '-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: A new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution, Bioorg. Med. Chem. Lett, 16, 3298, 10.1016/j.bmcl.2006.03.026

H. Zheng, 2005, Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: <i>in vitro</i> studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition, J. Neurochem, 95, 68, 10.1111/j.1471-4159.2005.03340.x

D. Kaur, 2003, Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease, Neuron, 37, 899, 10.1016/S0896-6273 (03)00126-0

R. Cherny, 2001, Treatment with a copper-zinc chelator markedly and rapidly inhibits [beta]-amyloid accumulation in Alzheimer's disease transgenic mice, Neuron, 30, 665, 10.1016/S0896-6273(01)00317-8

H. Zheng, 2005, Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases, J. Pept. Res, 66, 190, 10.1111/j.1399-3011.2005.00289.x

C. Deraeve, 2007, Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents, New J. Chem, 31, 193, 10.1039/b616085a

C. Ritchie, 2003, Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial, Arch. Neurol, 60, 1685, 10.1001/archneur.60.12.1685

A. Bush, 2002, Metal complexing agents as therapies for Alzheimer's disease, Neurobiol. Aging, 23, 1031, 10.1016/S0197-4580(02)00120-3

J. Tateishi, Subacute myelo-optico-neuropathy: Clioquinol intoxication in humans and animals, Neuropathology, 20, 10.1046/j.1440-1789.2000.00296.x

M. Yassin, 2000, Changes in uptake of vitamin B-12 and trace metals in brains of mice treated with clioquinol, J. Neurol. Sci, 173, 40, 10.1016/S0022-510X(99)00297-X

M. Di Vaira, 2004, Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: Structural characterization of its zinc(II) and copper(II) complexes, Inorg. Chem, 43, 3795, 10.1021/ic0494051

C. Wagner, 2007, Vibrational spectra of clioquinol and its Cu(II) complex, J. Raman Spectrosc, 38, 373, 10.1002/jrs.1654

A. Budimir, Hydroxyquinoline based binders: Promising ligands for chelatotherapy?, J. Inorg. Biochem, 10.1016/j.jinorgbio.2010.08.014

R. Cherny, 1999, Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion, J. Biol. Chem, 274, 23223, 10.1074/jbc.274.33.23223

C. Grossi, 2009, Clioquinol decreases amyloid-β burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease, J. Alzheimer's Dis, 17, 423, 10.3233/JAD-2009-1063

L. Lannfelt, 2008, Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial, Lancet Neurol, 7, 779, 10.1016/S1474-4422(08)70167-4

P. Adlard, 2008, Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ, Neuron, 59, 43, 10.1016/j.neuron.2008.06.018